Song Guisheng is currently a permanent professor and doctoral supervisor at the Medical School of the University of Minnesota Twin Cities, as well as chief scientist of a micro molecule RNA drug development team. Song graduated from Shanxi University in 2001.

In 1996, Song obtained a bachelor’s degree from Shanxi Normal University.

From 1998 to 2001, Song studied at Shanxi University and obtained a master’s degree from the university’s Biotechnology Research Institute.

In 2205, Song obtained his doctorate from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences.

From 2006 to 2012, Song worked at the University of California at San Francisco.

Since 2013, Song has been working at the Medical School at the University of Minnesota Twin Cities.

Song is the prize winner of the American Cancer Society Scholar Award and the United States National Institutes of Health Translational Medicine Scholar Award.

Song Guisheng has long been committed to the study of translational medicine of liver cancer, non-alcoholic steatohepatitis and rectal cancer. His laboratory combines genome editing, bioinformatics and translational medicine, focusing on the roles and molecular mechanisms of micro RNAs in the liver and major gastrointestinal diseases, and the development of related drugs.

After years of research, Song’s research team has accurately obtained Micro-226, which can diagnose liver cancer and inhibit liver cancer significantly. This not only provides a new clinical marker for early diagnosis and detection of hepatocellular carcinoma, but also can be used as a judgment for hepatocellular carcinoma.

The tools for clinical malignant phenotypes and prognosis are potential tools for the development of timely and effective preventive and therapeutic measures and are of great significance for the comprehensive treatment of patients with hepatocellular carcinoma.

Song has also published dozens of academic papers leading international academic journals.